NASDAQ:IDXG

Interpace Diagnostics Group Stock Insider Trading

Healthcare > Medical - Diagnostics & Research

Buy IDXG

*Your capital is at risk

$1.75

-0.0100 (-0.568%)

At Close: Jun 03, 2026

Interpace Diagnostics Group Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -65.06. In total, the insiders bought 24.93M and sold 141K IDXG shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-65.06
● Buy	24.93M shares
● Sell	141K shares
94% Buy Activity Negligible or No Correlation
No Significant Signals No statistically significant buy or sell signals detected in recent insider data.

Historical Insider Trades

Date	Type	Person	Role	Amount
Jan 20, 2026 Sell	Series C Convertible Preferred Stock C-Conversion	1315 Capital Ii, L.p. 10 Percent Owner	10% Owner	19 000 Value: $38.4K
Jan 20, 2026 Buy	Common Stock C-Conversion	1315 Capital Ii, L.p. 10 Percent Owner	10% Owner	9 405 941 Value: $19.0M
Jan 20, 2026 Buy	Common Stock C-Conversion	Ampersand 2018 Limited Partnership 10 Percent Owner	10% Owner	13 861 386 Value: $28.0M
Jan 20, 2026 Sell	Series C Convertible Preferred Stock C-Conversion	Ampersand 2018 Limited Partnership 10 Percent Owner	10% Owner	28 000 Value: $56.6K
Dec 01, 2024 Buy	Common Stock M-Exempt	Mccarthy Christopher Chief Financial Officer	C-Suite Officer	1 111 Value: $2K
Dec 01, 2024 Buy	Common Stock M-Exempt	Mccarthy Christopher Chief Financial Officer	C-Suite Officer	1 111 Value: $2K
Oct 11, 2024 Buy	Series C Convertible Preferred Stock A-Award	1315 Capital Ii, L.p. 10 Percent Owner	10% Owner	19 000 Value: $38.4K
Oct 11, 2024 Sell	Series B Convertible Preferred Stock D-Return	1315 Capital Ii, L.p. 10 Percent Owner	10% Owner	19 000 Value: $114.0K
Oct 11, 2024 Buy	Series C Convertible Preferred Stock A-Award	Ampersand 2018 Limited Partnership 10 Percent Owner	10% Owner	28 000 Value: $56.6K
Oct 11, 2024 Sell	Series B Convertible Preferred Stock D-Return	Ampersand 2018 Limited Partnership 10 Percent Owner	10% Owner	28 000 Value: $168.0K
Oct 11, 2024 Sell	Series B Convertible Preferred Stock D-Return	Ampersand 2018 Limited Partnership 10 Percent Owner	10% Owner	28 000 Value: $168.0K
Oct 11, 2024 Buy	Series C Convertible Preferred Stock A-Award	Ampersand 2018 Limited Partnership 10 Percent Owner	10% Owner	28 000 Value: $56.6K
Oct 11, 2024 Sell	Series B Convertible Preferred Stock D-Return	1315 Capital Ii, L.p. 10 Percent Owner	10% Owner	19 000 Value: $114.0K
Oct 11, 2024 Buy	Series C Convertible Preferred Stock A-Award	1315 Capital Ii, L.p. 10 Percent Owner	10% Owner	19 000 Value: $38.4K
Jul 27, 2024 Buy	Common Stock M-Exempt	Mccarthy Christopher Chief Financial Officer	C-Suite Officer	15 112 Value: $26.4K
Jul 27, 2024 Buy	Common Stock M-Exempt	Mccarthy Christopher Chief Financial Officer	C-Suite Officer	15 112 Value: $26.4K
Feb 01, 2024 Buy	Common Stock M-Exempt	Mccarthy Christopher Chief Financial Officer	C-Suite Officer	6 045 Value: $0
Feb 01, 2024 Buy	Common Stock M-Exempt	Mccarthy Christopher Chief Financial Officer	C-Suite Officer	6 045 Value: $0
Feb 01, 2024 Buy	Common Stock A-Award	Mccarthy Christopher Chief Financial Officer	C-Suite Officer	10 000 Value: $0
Feb 01, 2024 Buy	Common Stock A-Award	Mccarthy Christopher Chief Financial Officer	C-Suite Officer	10 000 Value: $0
Jan 31, 2024 Buy	Common Stock M-Exempt	Mccarthy Christopher Chief Financial Officer	C-Suite Officer	7 556 Value: $0
Jan 31, 2024 Buy	Common Stock M-Exempt	Mccarthy Christopher Chief Financial Officer	C-Suite Officer	7 556 Value: $0
Dec 01, 2023 Buy	Common Stock M-Exempt	Mccarthy Christopher Chief Financial Officer	C-Suite Officer	1 095 Value: $0
Dec 01, 2023 Buy	Common Stock M-Exempt	Mccarthy Christopher Chief Financial Officer	C-Suite Officer	1 095 Value: $0
Jul 31, 2023 Buy	Common Stock M-Exempt	Mccarthy Christopher Chief Financial Officer	C-Suite Officer	7 556 Value: $0

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT INTERPACE DIAGNOSTICS GROUP

Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; PanDNA, a molecular only version of PancraGEN that provides physicians a snapshot of a limited n...

Read Full Profile Here